Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure.
OBJECTIVE
To test the hypothesis that myocardium specific proteins may be useful markers for evaluating the severity of congestive heart failure.


METHODS
Serum concentrations of myosin light chain I (MLC-I), heart fatty acid binding protein (H-FABP), creatine kinase isoenzyme MB (CK-MB), and troponin T (TnT) and plasma concentrations of brain natriuretic peptide (BNP) were determined in 48 patients with acute deterioration of congestive heart failure, both before and after effective treatment.


RESULTS
Before treatment, MLC-I (mean (SEM) 3.2 (2.2) microg/l), H-FABP (9.0 (3.5) microg/l), TnT (30 (21) ng/l), and BNP (761 (303) ng/l) were higher than the normal reference range, and concentrations of CK-MB (5.4 (2.9) microg/l) were near normal. Treatment of congestive heart failure with conventional medication significantly decreased the concentrations of MLC-I (1.2 (0.3) microg/l, p < 0.0001), H-FABP (6.0 (2.0) microg/l, p < 0.0001), CK-MB (2.9 (1.5) microg/l, p < 0.0001), TnT (9 (1) ng/l, p < 0.001), and BNP (156 (118) ng/l, p < 0.0001). The decreases in H-FABP and CK-MB concentrations after treatment correlated with the decrease in BNP concentrations (p < 0.05). The absolute concentrations of MLC-I, H-FABP, CK-MB, and TnT correlated positively with those of BNP (p < 0.01).


CONCLUSIONS
These findings suggest that MLC-I, H-FABP, CK-MB, and TnT may be used as reliable markers for the evaluation of the severity of congestive heart failure.
Goto
T
T
Department of Internal Medicine, Enshu General Hospital, Hamamatsu, Japan.
Takase
H
H
Toriyama
T
T
Sugiura
T
T
Sato
K
K
Ueda
R
R
Dohi
Y
Y
D000368:Aged; D015415:Biomarkers / Q000097:blood; D002352:Carrier Proteins / Q000097:blood*; D003402:Creatine Kinase / Q000097:blood*; D052279:Creatine Kinase, MB Form; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D008297:Male; D018994:Myosin Light Chains / Q000097:blood*; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D009363:Neoplasm Proteins; D011379:Prognosis; D020107:Troponin T / Q000097:blood*; D025521:Tumor Suppressor Proteins
D015415:Biomarkers; D002352:Carrier Proteins; C107608:FABP7 protein, human; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D007527:Isoenzymes; D018994:Myosin Light Chains; D009363:Neoplasm Proteins; D020107:Troponin T; D025521:Tumor Suppressor Proteins; C491915:hALC-1 protein, human; D020097:Natriuretic Peptide, Brain; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form